Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: Results of a phase II, randomized, placebo-controlled, dose-finding trial

Arthritis and Rheumatism

Volumn 63, Issue 7, 2011, Pages 1793-1803

  Genovese, M C ^a   Kinnman, N ^b   De La Bourdonnaye, G ^b   Pena Rossi, C ^b   Tak, P P ^c  

^a STANFORD UNIVERSITY   (United States)

^b MERCK SERONO S A   (Switzerland)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ATACICEPT; C REACTIVE PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLIXIMAB; PLACEBO; PROTEIN ANTIBODY; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; BLOOD DISEASE; BREAST DISEASE; BRONCHITIS; CARDIOPULMONARY INSUFFICIENCY; COMPLICATION; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; GENITAL SYSTEM DISEASE; GRAM NEGATIVE INFECTION; HEART DISEASE; HUMAN; IMMUNIZATION; IMMUNOPATHOLOGY; INJURY; INTOXICATION; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; PHASE 2 CLINICAL TRIAL; PNEUMOTHORAX; PRIORITY JOURNAL; PROCEDURAL COMPLICATION; RESPIRATORY TRACT DISEASE; RHEUMATOID ARTHRITIS; SKIN DISEASE; STENOTROPHOMONAS INFECTION; THORAX DISEASE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULINS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; RHEUMATOID FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79959832697     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30373     Document Type: Article

References (44)

1. Klareskog L, Catrina AI, Paget S,. Rheumatoid arthritis. Lancet 2009; 373: 659-72.
2. Finckh A, Choi HK, Wolfe F,. Progression of radiographic joint damage in different eras: trends towards milder disease in rheumatoid arthritis are attributable to improved treatment. Ann Rheum Dis 2006; 65: 1192-7. (Pubitemid 44277395)
3. Van Vollenhoven RF,. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol 2009; 5: 531-41.
4. Bugatti S, Codullo V, Caporali R, Montecucco C,. B cells in rheumatoid arthritis. Autoimmun Rev 2007; 7: 137-42. (Pubitemid 350116726)
5. Dorner T, Kinnman N, Tak PP,. Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers. Pharmacol Ther 2010; 125: 464-75.
6. Edwards JC, Cambridge G,. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006; 6: 394-403.
7. Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999; 285: 260-3. (Pubitemid 29330000)
8. Dillon SR, Gross JA, Ansell SM, Novak AJ,. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 2006; 5: 235-46. (Pubitemid 43336036)
9. Bossen C, Cachero TG, Tardivel A, Ingold K, Willen L, Dobles M, et al. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood 2008; 111: 1004-12. (Pubitemid 351213377)
10. 2 class switching by inducing epithelial-cell secretion of the cytokine APRIL. Immunity 2007; 26: 812-26. (Pubitemid 46915505)
11. Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P, et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002; 3: 822-9.
12. Thompson JS, Schneider P, Kalled SL, Wang L, Lefevre EA, Cachero TG, et al. BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. J Exp Med 2000; 192: 129-35. (Pubitemid 30470814)
13. Do RK, Hatada E, Lee H, Tourigny MR, Hilbert D, Chen-Kiang S,. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med 2000; 192: 953-64.
14. Batten M, Groom J, Cachero TG, Qian F, Schneider P, Tschopp J, et al. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 2000; 192: 1453-66.
15. Hsu BL, Harless SM, Lindsley RC, Hilbert DM, Cancro MP,. Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol 2002; 168: 5993-6. (Pubitemid 34620011)
16. Cheema GS, Roschke V, Hilbert DM, Stohl W,. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001; 44: 1313-9. (Pubitemid 32537529)
17. Roschke V, Sosnovtseva S, Ward CD, Hong JS, Smith R, Albert V, et al. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 2002; 169: 4314-21. (Pubitemid 35178204)
18. Marsters SA, Yan M, Pitti RM, Haas PE, Dixit VM, Ashkenazi A,. Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol 2000; 10: 785-8. (Pubitemid 30466942)
19. Dillon SR, Harder B, Lewis KB, Moore MD, Liu H, Bukowski TR, et al. B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin. Arthritis Res Ther 2010; 12: R48.
20. Gross JA, Dillon SR, Mudri S, Johnston J, Littau A, Roque R, et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS. Immunity 2001; 15: 289-302. (Pubitemid 32816877)
21. Wang H, Marsters SA, Baker T, Chan B, Lee WP, Fu L, et al. TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat Immunol 2001; 2: 632-7. (Pubitemid 32677631)
22. Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, et al, and the Merck Serono and ZymoGenetics Atacicept Study Group. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007; 56: 4142-50. (Pubitemid 350262342)
23. Ansell SM, Witzig TE, Inwards DJ, Porrata LF, Ythier A, Ferrande L, et al. Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma. Clin Cancer Res 2008; 14: 1105-10. (Pubitemid 351302557)
24. Munafo A, Priestley A, Nestorov I, Visich J, Rogge M,. Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers. Eur J Clin Pharmacol 2007; 63: 647-56. (Pubitemid 46911347)
25. Nestorov I, Papasouliotis O, Pena RC, Munafo A,. Pharmacokinetics and immunoglobulin response of subcutaneous and intravenous atacicept in patients with systemic lupus erythematosus. J Pharm Sci 2010; 99: 524-38.
26. Tak PP, Thurlings RM, Rossier C, Nestorov I, Dimic A, Mircetic V, et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum 2008; 58: 61-72.
27. Smith RM, Clatworthy MR, Jayne DR,. Biological therapy for lupus nephritis: tribulations and trials. Nat Rev Rheumatol 2010; 6: 547-52.
28. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24. (Pubitemid 18091653)
29. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
30. Prevoo ML, Van 't Hof MA, Kuper HH, Van Leeuwen MA, Van De Putte LB, Van Riel PL,. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
31. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993; 36: 729-40. (Pubitemid 23175613)
32. Bracewell C, Isaacs JD, Emery P, Ng WF,. Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis. Expert Opin Biol Ther 2009; 9: 909-19.
33. Stohl W, Chatham W, Weisman M, Furie R, Weinstein A, Mishra N, et al, and the LBRA01 Study Group. Belimumab (BmAb), a novel fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), selectively modulates B-cell subpopulations and immunoglobulins in a heterogeneous rheumatoid arthritis population [abstract]. Arthritis Rheum 2005; 52 Suppl: S444.
34. Benson MJ, Dillon SR, Castigli E, Geha RS, Xu S, Lam KP, et al. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol 2008; 180: 3655-9.
35. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al, for the REFLEX trial group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-806. (Pubitemid 44497758)
36. Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, Tak PP,. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis 2008; 67: 917-25. (Pubitemid 351956651)
37. Dass S, Vital EM, Emery P,. Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis. Expert Opin Pharmacother 2006; 7: 2559-70. (Pubitemid 44932458)
38. Kim HJ, Krenn V, Steinhauser G, Berek C,. Plasma cell development in synovial germinal centers in patients with rheumatoid and reactive arthritis. J Immunol 1999; 162: 3053-62. (Pubitemid 29309336)
39. Tan SM, Xu D, Roschke V, Perry JW, Arkfeld DG, Ehresmann GR, et al. Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum 2003; 48: 982-92. (Pubitemid 36418240)
40. Gabay C, Krenn V, Bosshard C, Seemayer CA, Chizzolini C, Huard B,. Synovial tissues concentrate secreted APRIL. Arthritis Res Ther 2009; 11: R144.
41. Nestorov I, Munafo A, Papasouliotis O, Visich J,. Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis. J Clin Pharmacol 2008; 48: 406-17. (Pubitemid 351389119)
42. Clavel C, Nogueira L, Laurent L, Iobagiu C, Vincent C, Sebbag M, et al. Induction of macrophage secretion of tumor necrosis factor α through FcÎ receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen. Arthritis Rheum 2008; 58: 678-88. (Pubitemid 351364865)
43. Van Vollenhoven R, Vincent E, Wax S, Kinnman N, Bathon J,. Efficacy and safety of atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the AUGUST II study [abstract]. EULAR Annual European Congress of Rheumatology, 16-19 June 2010; Rome, Italy.
44. Van Vollenhoven RF, Kinnman N, Vincent E, Wax S, Bathon J,. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial. Arthritis Rheum 2011; 63: 1782-92.